Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.42 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 6/20 | 0.55 |
| ▸ | HTR2B | P41595 | 5/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.46 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.46 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.46 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.46 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.46 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.46 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.46 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.46 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | PNMT | P11086 | 3/20 | 0.42 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1947625 | 0.98 | HTR2C (0.57) | HTR2CHTR2BHTR2AADCY6ADCY3 | |
| Hydrochloric Acid SCHEMBL8178179 | 0.96 | HTR2C (0.55) | HTR2CHTR2BHTR2AADCY6ADCY3 | |
| SCHEMBL329985 | 0.85 | ASIC3 (0.60) | DRD2PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL29657674 | 0.85 | ASIC3 (0.60) | DRD2PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL29521679 | 0.85 | PNMT (0.60) | DRD2PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL330080 | 0.85 | PNMT (0.60) | DRD2PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL4517857 | 0.83 | PNMT (0.58) | DRD2PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL3285222 | 0.83 | PNMT (0.58) | DRD2PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL1948668 | 0.83 | ASIC3 (0.58) | DRD2PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL4514463 | 0.83 | ASIC3 (0.58) | DRD2PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | LECTUS THERAPEUTICS LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | LECTUS THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| EP-2069309-A1 | ION CHANNEL MODULATORS&USES THEREOF | Lectus Therapeutics Limited (GB) | 2009-06-17 | — | — | EP | disclosed |
| EP-2066317-A2 | USE OF ION CHANNEL MODULATORS IN THE PROPHYLAXIS AND TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISEASES | Lectus Therapeutics Limited (GB) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008038051-A2 | USE OF ION CHANNEL MODULATORS IN THE PROPHYLAXIS AND TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISEASES | LECTUS THERAPEUTICS LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008038053-A1 | ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | KCNH3, KCNN3, KCNH2 | ADRA2A 220/4885ADRA2B 211/4885ADRA2C 165/4885 |
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | HCAR2, HCAR1, SCN7A | ADRA2A 502/4885ADRA2B 390/4885ADRA2C 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.